MarketPulse
O

$OGN

3 articles found
0 positive
1 negative
2 neutral
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Investor Bet on Organon Stock Signals Turnaround Faith Despite 61% Collapse

Sio Capital Management invested $24.53 million in Organon ($OGN) at $6.03/share, betting on turnaround potential despite 61% annual decline. Company maintains flat 2026 guidance with $1.9B adjusted EBITDA.
OGNvalue investinginstitutional investment
GlobeNewswire Inc.GlobeNewswire Inc.··Kdventures Ab

Organon Discontinues Second Forendos Drug Candidate, KDventures Faces Total Loss

Organon discontinues second Forendo drug candidate for PCOS, eliminating all programs from 2021 acquisition. KDventures writes off remaining contingent consideration entirely.
OGNpharmaceutical developmentdrug development discontinuation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Organon Scraps PCOS Drug Candidate, Dealing Second Blow to KDventures' Forendo Bet

Organon discontinues PCOS drug candidate, marking total failure of KDventures' 2021 Forendo acquisition. Contingent consideration fully written off after second portfolio termination.
OGNdrug development discontinuationForendo acquisition